Published in Biotech Law Weekly, July 2nd, 2004
Skaletsky will bring extensive biotechnology and business expertise to the Alkermes board, and he qualifies as an independent director as defined under the Sarbanes Oxley Act of 2002 and the NASDAQ stock exchange regulations.
Skaletsky has more than 30 years of experience serving in executive management positions and leading major growth and acquisition activities for biotech and pharmaceutical companies. Skaletsky is currently chairman, CEO and president of Trine Pharmaceuticals, Inc., a privately held drug development company.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.